Paradigm shifting vaccines: Prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer

Current Opinion in Virology

Volumn 1, Issue 4, 2011, Pages 268-279

  Frazer, Ian H ^a   Levin, Myron J ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Pediatric Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; NEUTRALIZING ANTIBODY; PLACEBO; PROTEIN E6; PROTEIN E7; VARICELLA ZOSTER VACCINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ANTIBODY TITER; ANUS INTRAEPITHELIAL NEOPLASIA; ARTICLE; CANCER MORTALITY; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONDYLOMA ACUMINATUM; DAILY LIFE ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITHELIUM CELL; GROUPS BY AGE; HEALTH CARE COST; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; LATENT VIRUS INFECTION; MALIGNANT TRANSFORMATION; MASS IMMUNIZATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATHOPHYSIOLOGY; POSTHERPETIC NEURALGIA; PRECANCER; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUALLY TRANSMITTED DISEASE; SKIN CANCER; UTERINE CERVICITIS; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION REACTION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VULVA INTRAEPITHELIAL NEOPLASIA;

EID: 80053380291     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.07.007     Document Type: Review

References (72)

1. M.N. de Koning, L. Struijk, J.N. Bavinck, B. Kleter, S.J. Ter, W.G. Quint, and M.C. Feltkamp Betapapillomaviruses frequently persist in the skin of healthy individuals J Gen Virol 88 Pt 5 2007 1489 1495 (Pubitemid 46723231)
2. N. Munoz, F.X. Bosch, X. Castellsague, M. Diaz, S.S. de, D. Hammouda, K.V. Shah, and C.J. Meijer Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int J Cancer 111 2004 278 285 (Pubitemid 38924707)
3. T.C. Wright Jr. Natural history of HPV infections J Fam Pract 58 9 Suppl. HPV 2009 S3 S7
4. F.X. Bosch, A.N. Burchell, M. Schiffman, A.R. Giuliano, S.S. de, L. Bruni, G. Tortolero-Luna, S.K. Kjaer, and N. Munoz Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia Vaccine 26 Suppl. 10 2008 K1 K16
5. H. Pfister Chapter 8: human papillomavirus and skin cancer J Natl Cancer Inst Monogr 2003 2003 52 56
6. J.N. Bouwes Bavinck, and R.J. Berkhout HPV infections and immunosuppression Clin Dermatol 15 1997 427 437 (Pubitemid 27334835)
7. C.M. Hebner, and L.A. Laimins Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity Rev Med Virol 16 2006 83 97
8. A.E. Griep, R. Herber, S. Jeon, J.K. Lohse, R.R. Dubielzig, and P.F. Lambert Tumorigenicity by human papillomavirus type 16 E6 and E7 in transgenic mice correlates with alterations in epithelial cell growth and differentiation J Virol 67 1993 1373 1384 (Pubitemid 23067644)
9. M.I. Van Poelgeest, E.R. Nijhuis, K.M. Kwappenberg, I.E. Hamming, D.J. Wouter, G.J. Fleuren, A.G. van der Zee, C.J. Melief, G.G. Kenter, and H.W. Nijman Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia Int J Cancer 118 2006 675 683 (Pubitemid 43076017)
10. I. Jochmus-Kudielka, A. Schneider, R. Braun, R. Kimmig, U. Koldovsky, K.E. Schneweis, K. Seedorf, and L. Gissmann Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer J Natl Cancer Inst 81 1989 1698 1704 (Pubitemid 19275907)
11. J.J. Carter, M.M. Madeleine, K. Shera, S.M. Schwartz, K.L. Cushing-Haugen, G.C. Wipf, P. Porter, J.R. Daling, J.K. McDougall, and D.A. Galloway Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites Cancer Res 61 2001 1934 1940 (Pubitemid 32692010)
12. J.J. Carter, L.A. Koutsky, J.P. Hughes, S.K. Lee, J. Kuypers, N. Kiviat, and D.A. Galloway Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection J Infect Dis 181 2000 1911 1919 (Pubitemid 30416152)
13. C.B. Buck, N. Cheng, C.D. Thompson, D.R. Lowy, A.C. Steven, J.T. Schiller, and B.L. Trus Arrangement of L2 within the papillomavirus capsid J Virol 82 2008 5190 5197 (Pubitemid 351705228)
14. J.J. Orozco, J.J. Carter, L.A. Koutsky, and D.A. Galloway Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers J Virol 79 2005 9503 9514 (Pubitemid 41022294)
15. X.S. Chen, R.L. Garcea, I. Goldberg, G. Casini, and S.C. Harrison Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16 Mol Cell 5 2000 557 567
16. S.E. Olsson, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.R. Brown, L.A. Koutsky, and E.H. Tay Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection Hum Vac 5 2009
17. H. zur Hausen Papillomaviruses in the causation of human cancers - a brief historical account Virology 384 2009 260 265
18. A. Anttila, L. Kotaniemi-Talonen, M. Leinonen, M. Hakama, P. Laurila, J. Tarkkanen, N. Malila, and P. Nieminen Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme BMJ 340 2010 c1804
19. J. Zhou, X.Y. Sun, D.J. Stenzel, and I.H. Frazer Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles Virology 185 1991 251 257
20. I.H. Frazer, and J. Cox Finding a vaccine for human papillomavirus Lancet 367 2006 2058 2059
21. R. Kirnbauer, J. Taub, H. Greenstone, R. Roden, M. D'rst, L. Gissmann, D.R. Lowy, and J.T. Schiller Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles J Virol 67 1993 6929 6936 (Pubitemid 23343814)
22. T.G. Evans, W. Bonnez, R.C. Rose, S. Koenig, L. Demeter, J.A. Suzich, D. O'Brien, M. Campbell, W.I. White, and J. Balsley A phase 1 study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers J Infect Dis 183 2001 1485 1493 (Pubitemid 32417699)
23. D. Nardelli-Haefliger, D. Wirthner, J.T. Schiller, D.R. Lowy, A. Hildesheim, F. Ponci, and G.P. De Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles JNCI-J Natl Cancer Inst 95 2003 1128 1137 (Pubitemid 37045391)
24. J.A. Suzich, S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura, J.A. Bell, J.A. Newsome, A.B. Jenson, and R. Schlegel Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas Proc Natl Acad Sci USA 92 1995 11553 11557 (Pubitemid 26014152)
25. J.T. Schiller, P.M. Day, and R.C. Kines Current understanding of the mechanism of HPV infection Gynaecol Oncol 118 1 Suppl. 2010 S12 S17
26. R.S. Lowe, D.R. Brown, J.T. Bryan, J.C. Cook, H.A. George, K.J. Hofmann, W.M. Hurni, J.G. Joyce, E.D. Lehman, and H.Z. Markus Human papillomavirus type II (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast J Infect Dis 176 1997 1141 1145 (Pubitemid 27460976)
27. R.B. Roden, W.H. Yutzy, R. Fallon, S. Inglis, D.R. Lowy, and J.T. Schiller Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes Virology 270 2000 254 257 (Pubitemid 30333671)
28. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, and N.S. De Carvalho Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 2004 1757 1765 (Pubitemid 39488060)
29. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, and N.S. De Carvalho Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized, controlled trial Obstet Gynecol Surv 60 2005 303 305
30. L.L. Villa, R.L. Costa, C.A. Petta, R.P. Andrade, K.A. Ault, A.R. Giuliano, C.M. Wheeler, L.A. Koutsky, C. Malm, and M. Lehtinen Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 6 2005 271 278 (Pubitemid 40590263)
31. J. Paavonen, D. Jenkins, F.X. Bosch, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, D.L. Apter, H.C. Kitchener, and X. Castellsague Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 2007 2161 2170 (Pubitemid 46977438)
32. E.A. Joura, S. Leodolter, M. Hernandez-Avila, C.M. Wheeler, G. Perez, L.A. Koutsky, S.M. Garland, D.M. Harper, G.W. Tang, and D.G. Ferris Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials Lancet 369 2007 1693 1702 (Pubitemid 46783792)
33. K.A. Ault Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials Lancet 369 2007 1861 1868 (Pubitemid 46829356)
34. The Future 2 study group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 2007 1915 1927
35. N. Munoz, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler, G. Perez, D.R. Brown, L.A. Koutsky, and E.H. Tay Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women J Natl Cancer Inst 102 2010 325 339
36. N. Munoz, R. Manalastas Jr., P. Pitisuttithum, D. Tresukosol, J. Monsonego, K. Ault, C. Clavel, J. Luna, E. Myers, and S. Hood Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial Lancet 373 2009 1949 1957
37. D.R. Brown, S.K. Kjaer, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, C.M. Wheeler, G. Perez, L.A. Koutsky, E.H. Tay, and P. Garcia The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years J Infect Dis 199 2009 926 935
38. P. Bonanni, S. Boccalini, and A. Bechini Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence Vaccine 27 Suppl. 1 2009 A46 A53
39. A. Hildesheim, R. Herrero, S. Wacholder, A.C. Rodriguez, D. Solomon, M.C. Bratti, J.T. Schiller, P. Gonzalez, G. Dubin, and C. Porras Effect of human papillomavirus 16/18 L1 virus like particle vaccine among young women with preexisting infection: a randomized trial J Am Med Assoc 298 2007 743 753 (Pubitemid 47263157)
40. S.E. Olsson, L.L. Villa, R.L. Costa, C.A. Petta, R.P. Andrade, C. Malm, O.E. Iversen, J. Hoye, M. Steinwall, and G. Riis-Johannessen Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine Vaccine 25 2007 4931 4939 (Pubitemid 46843434)
41. E.A. Joura, S.K. Kjaer, C.M. Wheeler, K. Sigurdsson, O.E. Iversen, M. Hernandez-Avila, G. Perez, D.R. Brown, L.A. Koutsky, and E.H. Tay HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine Vaccine 26 2008 6844 6851
42. L.E. Markowitz, S. Hariri, E.R. Unger, M. Saraiya, S.D. Datta, and E.F. Dunne Post-licensure monitoring of HPV vaccine in the United States Vaccine 28 2010 4731 4737
43. J.M. Brotherton, M.S. Gold, A.S. Kemp, P.B. McIntyre, M.A. Burgess, and S. Campbell-Lloyd Anaphylaxis following quadrivalent human papillomavirus vaccination CMAJ 179 2008 525 533
44. B. Donovan, N. Franklin, R. Guy, A.E. Grulich, D.G. Regan, H. Ali, H. Wand, and C.K. Fairley Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data Lancet Infect Dis 11 2010 39 44
45. P. Bonanni, C. Cohet, S.K. Kjaer, N.B. Latham, P.H. Lambert, K. Reisinger, and R.M. Haupt A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD((R)) Vaccine 28 2010 4719 4730
46. T. Zhang, Y. Xu, L. Qiao, Y. Wang, X. Wu, D. Fan, Q. Peng, and X. Xu Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types Vaccine 28 2010 3479 3487
47. T. Vesikari, D.P. Van, N. Lindblad, U. Pfletschinger, D. Radley, D. Ryan, S. Vuocolo, R.M. Haupt, and D. Guris An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age Pediatr Infect Dis J 29 2010 314 318
48. M.N. Oxman, M.J. Levin, G.R. Johnson, K.E. Schmader, S.E. Straus, L.D. Gelb, R.D. Arbeit, M.S. Simberkoff, A.A. Gershon, and L.E. Davis A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med 352 2005 2271 2284
49. B.P. Yawn, P. Saddier, P.C. Wollan, J.L. St Sauver, M.J. Kurland, and L.S. Sy A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction Mayo Clin Proc 82 2007 1341 1349 (Pubitemid 350060129)
50. R.G. Kost, and S.E. Straus Postherpetic neuralgia - pathogenesis, treatment, and prevention N Engl J Med 335 1996 32 42 (Pubitemid 26230812)
51. R.R. White, G. Lenhart, P.K. Singhal, R.P. Insinga, R.F. Itzler, J.M. Pellissier, and A.W. Segraves Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans Pharmacoeconomics 27 2009 781 792
52. K.E. Schmader, G.R. Johnson, P. Saddier, M. Ciarleglio, W.W. Wang, J.H. Zhang, I.S. Chan, S.S. Yeh, M.J. Levin, and R.M. Harbecke Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults J Am Geriatr Soc 58 2010 1634 1641
53. A.K. Satyaprakash, A.M. Tremaine, A.A. Stelter, R. Creed, P. Ravanfar, N. Mendoza, S.K. Mehta, P.L. Rady, D.L. Pierson, and S.K. Tyring Viremia in acute herpes zoster J Infect Dis 200 2009 26 32
54. M.N. Oxman Zoster vaccine: current status and future prospects Clin Infect Dis 51 2010 197 213
55. M.J. Levin, G.Y. Cai, M.D. Manchak, and L.I. Pizer Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia J Virol 77 2003 6979 6987 (Pubitemid 36666890)
56. M.L. Quinlivan, K. Ayres, H. Ran, S. McElwaine, M. Leedham-Green, F.T. Scott, R.W. Johnson, and J. Breuer Effect of viral load on the outcome of herpes zoster J Clin Microbiol 45 2007 3909 3914 (Pubitemid 350274869)
57. J.W. Gnann Herpes simplex and varicella-zoster virus infection after hematopoietic stem cell or solid organ transplantation R. Bowden, P. Ljungman, D. Snydman, Transplant Infections 2010 Lippincott, Williams & Wilkins Philadelphia 391 410
58. M. Takahashi, S. Okada, H. Miyagawa, K. Amo, K. Yoshikawa, H. Asada, H. Kamiya, S. Torigoe, Y. Asano, and T. Ozaki Enhancement of immunity against VZV by giving live varicella vaccine to the elderly assessed by VZV skin test and IAHA, gpELISA antibody assay Vaccine 21 2003 3845 3853 (Pubitemid 37338212)
59. A. Weinberg, A.A. Lazar, G.O. Zerbe, A.R. Hayward, I.S. Chan, R. Vessey, J.L. Silber, R.R. MacGregor, K. Chan, and A.A. Gershon Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses J Infect Dis 201 2010 1024 1030
60. M.J. Levin, and A.R. Hayward The varicella vaccine. Prevention of herpes zoster Infect Dis Clin N Am 10 1996 657 675 (Pubitemid 26285293)
61. P.M. Coplan, K. Schmader, A. Nikas, I.S. Chan, P. Choo, M.J. Levin, G. Johnson, M. Bauer, H.M. Williams, and K.M. Kaplan Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory J Pain 5 2004 344 356 (Pubitemid 39164674)
62. R. Harbecke, M.N. Oxman, B.A. Arnold, C. Ip, G.R. Johnson, M.J. Levin, L.D. Gelb, K.E. Schmader, S.E. Straus, and H. Wang A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses J Med Virol 81 2009 1310 1322
63. M.J. Levin, M.N. Oxman, J.H. Zhang, G.R. Johnson, H. Stanley, A.R. Hayward, M.J. Caulfield, M.R. Irwin, J.G. Smith, and J. Clair Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine J Infect Dis 197 2008 825 835 (Pubitemid 351417005)
64. A. Weinberg, J.H. Zhang, M.N. Oxman, G.R. Johnson, A.R. Hayward, M.J. Caulfield, M.R. Irwin, J. Clair, J.G. Smith, and H. Stanley Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine J Infect Dis 200 2009 1068 1077
65. I.H. Frazer, G.R. Leggatt, and S.R. Mattarollo Prevention and treatment of papillomavirus-related cancers through immunization Annu Rev Immunol 29 2011 111 138
66. R.P. Insinga, R.F. Itzler, J.M. Pellissier, P. Saddier, and A.A. Nikas The incidence of herpes zoster in a United States administrative database J Gen Intern Med 20 2005 748 753 (Pubitemid 41141008)
67. H. de Melker, G. Berbers, S. Hahne, H. Rumke, S. van den Hof, A. de Wit, and H. Boot The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination Vaccine 24 2006 3946 3952
68. R.E. Hope-Simpson The nature of herpes zoster: a long-term study and a new hypothesis Proc R Soc Med 58 1965 9 20
69. A.N. Stein, H. Britt, C. Harrison, E.L. Conway, A. Cunningham, and C.R. Macintyre Herpes zoster burden of illness and health care resource utilisation in the Australian population aged 50 years and older Vaccine 27 2009 520 529
70. J.S. Jih, Y.J. Chen, M.W. Lin, Y.C. Chen, T.J. Chen, Y.L. Huang, C.C. Chen, D.D. Lee, Y.T. Chang, and W.J. Wang Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006 Acta Derm Venereol 89 2009 612 616
71. M. Brisson, W.J. Edmunds, B. Law, N.J. Gay, R. Walld, M. Brownell, L. Roos, and G. De Serres Epidemiology of varicella zoster virus infection in Canada and the United Kingdom Epidemiol Infect 127 2001 305 314 (Pubitemid 33019542)
72. M. Brisson, N.J. Gay, W.J. Edmunds, and N.J. Andrews Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox Vaccine 20 2002 2500 2507 (Pubitemid 34615588)